Page last updated: 2024-08-24

atorvastatin and Kidney Diseases

atorvastatin has been researched along with Kidney Diseases in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.89)	18.2507
2000's	18 (33.96)	29.6817
2010's	32 (60.38)	24.3611
2020's	2 (3.77)	2.80

Authors

Authors	Studies
Abdullaev, DEO; Gavrilko, AD; Krasheninin, DV; Kuslivyi, AM; Mezhonov, EM; Shalaev, SV; Shermuk, AA; Vyalkina, YA	1
Abid, L; Ayedi, F; Bahloul, A; Ben Mrad, I; Charfeddine, S; Charfi, R; Ellouze, T; Gargouri, R; Hammami, R; Jdidi, J; Kammoun, S; Masmoudi, O; Turki, M	1
de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK	1
Ababneh, MA; Al Demour, S; Alzoubi, KH; Hijjawi, TB; Rababa’h, AM	1
Cunha Miranda, JV; de Azevedo Neto, E; de Oliveira Chaves, I; Dias, LDES; Dorsa Pontes, HB; Dourado, DM; Durães Gomes Oliva, JV; Kato da Silva, BA; Marques Dos Santos, CH; Martins de Almeida, MH; Sampaio, TL; Serra da Cruz Vendas, G	1
Archer, DR; Ataga, KI; Brown, LA; Chappa, P; Yin, H; Zahr, RS	1
Cheng, Q; Liu, Y; Wang, X; Yang, G; Zhao, J	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Bolkent, S; Karatug Kacar, A; Oztay, F; Yildirim, M	1
El-Moselhy, MA; El-Sheikh, AA	1
Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S	1
Campese, VM	1
Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jo, SH; Kim, HJ; Lee, SH; Lee, SY; Song, YB	1
Arévalo, M; Docherty, NG; Eleno, N; Fuentes-Calvo, I; Grande, MT; López-Novoa, JM; Pérez-Barriocanal, F; Rodríguez-Peña, AB	1
Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK	1
Dawani, ML; Mahboob, T; Yasmeen, G	1
Pal, PB; Pal, S; Sarkar, A; Sil, PC	1
Caristo, ME; Ciavarella, LP; Citterio, F; Copponi, G; Crea, F; Cusumano, G; Giubilato, S; Liuzzo, G; Manchi, M; Romagnoli, J; Severino, A; Stigliano, E; Zannoni, GF	1
Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y	1
Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT	1
Jin, YZ; Min, R; Wang, Q; Zhang, XY; Zhou, X	1
Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K	1
Ando, D; Hirawa, N; Umemura, S; Yasuda, G	1
Melfi, R; Nusca, A; Patti, G; Sciascio, GD	1
Acikel, S; Aydinalp, A; Bal, U; Bayraktar, N; Muderrisoglu, H; Ozin, B; Sade, E; Yildirir, A	1
Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Tedeschi, D; Toso, A	1
Patti, G	1
Colonna, G; D'Ambrosio, A; Di Sciascio, G; Montinaro, A; Nusca, A; Pasceri, V; Patti, G; Ricottini, E	1
Sadat, U	1
Cheng, QL; Ye, P; Zhao, JH	1
Takagi, H; Umemoto, T	2
Teramoto, T	1
Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Li, X; Wang, X; Wang, Y; Wu, W; Yang, Z	1
Cao, S; Cui, K; Hou, Y; Wang, P; Zhang, L	1
Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A	1
Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM	1
Ravnskov, U	1
Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG	1
Asano, T; Hayakawa, M; Kosaka, T; Miyajima, A; Mizuguchi, Y	1
Hey-Hadavi, JH; Kuntze, E; Lepetri, B; Luo, D; Pittman, D; Silverman, P	1
Demova, H; Kluckova, H; Komers, R; Lecian, D; Lodererova, A; Teplan, V; Voska, L; Zdychova, J	1
Kiberd, BA	1
Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M	1
Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A	1
Coombes, JS; Fassett, RG; Oliver, KR; Summers, MJ	1
Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y	1
Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A	1
Campese, VM; Park, J	1
Paraskevas, KI	1
Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW	1
He, J; McCarter, RJ; Moudgil, A; Sgambat, K	1
Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ	1

Reviews

13 review(s) available for atorvastatin and Kidney Diseases

Article	Year
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Scientific reports, 2019, 11-12, Volume: 9, Issue:1 Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome	2019
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides	2014
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis, 2016, Volume: 254 Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2016
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future cardiology, 2010, Volume: 6, Issue:5 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2010
Contrast-induced nephropathy: do statins offer protection? Current opinion in cardiology, 2011, Volume: 26, Issue:4 Topics: Amidohydrolases; Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic	2011
A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease. International journal of cardiology, 2011, Oct-20, Volume: 152, Issue:2 Topics: Atorvastatin; Chronic Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic	2011
A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. International journal of cardiology, 2011, Dec-15, Volume: 153, Issue:3 Topics: Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Pitavastatin: clinical effects from the LIVES Study. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides	2011
Rosuvastatin-induced arrest in progression of renal disease. Cardiology, 2004, Volume: 102, Issue:1 Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials. The American journal of geriatric pharmacotherapy, 2006, Volume: 4, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Diseases; Male; Musculoskeletal Diseases; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies	2006
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. International urology and nephrology, 2008, Volume: 40, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome	2008
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta	1999

Trials

15 trial(s) available for atorvastatin and Kidney Diseases

Article	Year
Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial. PloS one, 2023, Volume: 18, Issue:5 Topics: Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Percutaneous Coronary Intervention; Prospective Studies; Treatment Outcome	2023
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta cardiologica, 2013, Volume: 68, Issue:5 Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey	2013
High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention. Journal of cardiovascular medicine (Hagerstown, Md.), 2015, Volume: 16, Issue:3 Topics: Aged; Atorvastatin; Contrast Media; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Middle Aged; Percutaneous Coronary Intervention	2015
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease. Iranian journal of kidney diseases, 2015, Volume: 9, Issue:1 Topics: Adult; Atorvastatin; Biomarkers; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney Diseases; Male; Middle Aged; Niacin; Nitrates; Pakistan; Pyrroles; Recovery of Function; Renal Artery; Time Factors; Treatment Outcome; Ultrasonography, Doppler	2015
[Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography]. Zhonghua xin xue guan bing za zhi, 2009, Volume: 37, Issue:5 Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles	2009
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome	2010
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy. Renal failure, 2010, Volume: 32, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Probucol; Prospective Studies; Pyrroles; Young Adult	2010
Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2010, Volume: 21, Issue:8 Topics: Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles	2010
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during an The American journal of cardiology, 2011, Jul-01, Volume: 108, Issue:1 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome	2011
Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology, 2012, Volume: 122, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Creatinine; Cystatin C; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Myocardial Infarction; Pyrroles	2012
[Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:11 Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Male; Middle Aged; Oxidative Stress; Pyrroles	2012
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles	2003
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Suppl 3 Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator	2006
Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy, 2007, Volume: 27, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cognition; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Diseases; Lipids; Male; Middle Aged; Neuropsychological Tests; Placebos; Predictive Value of Tests; Pyrroles; Regression Analysis	2007
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Pyrroles	2007

Other Studies

25 other study(ies) available for atorvastatin and Kidney Diseases

Article	Year
[Influence of Loading Dose Of Atorvastatin on the Risk of Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction]. Kardiologiia, 2023, Feb-28, Volume: 63, Issue:2 Topics: Atorvastatin; Contrast Media; Creatinine; Humans; Kidney Diseases; Retrospective Studies; ST Elevation Myocardial Infarction	2023
The Nephroprotective Effect of N-Acetyl-L-Cysteine and Atorvastatin against Imipenem induced Nephrotoxicity. Current molecular pharmacology, 2018, Volume: 11, Issue:2 Topics: Acetylcysteine; Animals; Antioxidants; Atorvastatin; Blood Urea Nitrogen; Creatinine; Glomerular Filtration Rate; Glycosuria; Imipenem; Kidney; Kidney Diseases; Male; Protective Agents; Proteinuria; Rats, Sprague-Dawley; Thiobarbituric Acid Reactive Substances; Urea	2018
Atorvastatin Protects Kidney from Remote Reperfusion Injury. Annals of vascular surgery, 2018, Volume: 46 Topics: Animals; Aorta, Abdominal; Atorvastatin; Combined Modality Therapy; Cytoprotection; Disease Models, Animal; Ischemic Postconditioning; Kidney; Kidney Diseases; Male; Protective Agents; Rats, Wistar; Regional Blood Flow; Reperfusion Injury; Time Factors	2018
Renal protection by atorvastatin in a murine model of sickle cell nephropathy. British journal of haematology, 2018, Volume: 181, Issue:1 Topics: Anemia, Sickle Cell; Animals; Atorvastatin; Disease Models, Animal; Female; Kidney; Kidney Diseases; Male; Mice; Mice, Mutant Strains; NADPH Oxidase 2; NADPH Oxidase 4	2018
Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 109 Topics: Animals; Atorvastatin; Blood Pressure; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation Mediators; Kidney Diseases; Male; Rats; Rats, Inbred SHR	2019
The effects of atorvastatin on the kidney injury in mice with pulmonary fibrosis. The Journal of pharmacy and pharmacology, 2019, Volume: 71, Issue:8 Topics: Animals; Atorvastatin; Bleomycin; Cell Proliferation; Disease Models, Animal; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Signal Transduction	2019
Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Atorvastatin; Chemical and Drug Induced Liver Injury; Down-Regulation; Doxorubicin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Up-Regulation	2014
Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy. BioMed research international, 2014, Volume: 2014 Topics: Angiotensin II; Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Heptanoic Acids; Humans; Kidney; Kidney Diseases; Mice; Monomeric GTP-Binding Proteins; Pyrroles; Receptor, Angiotensin, Type 1; Signal Transduction; Ureteral Obstruction	2014
Statin use in Australian children: a retrospective audit of four pediatric hospitals. Paediatric drugs, 2014, Volume: 16, Issue:5 Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2014
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways. Biochimie, 2015, Volume: 112 Topics: Animals; Apoptosis; Atorvastatin; Chemical and Drug Induced Liver Injury; Endoplasmic Reticulum; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Liver; Male; MAP Kinase Signaling System; Mice; Mitochondria, Liver; Oxidative Stress; Triterpenes	2015
N-Acetylcysteine and High-Dose Atorvastatin Reduce Oxidative Stress in an Ischemia-Reperfusion Model in the Rat Kidney. Transplantation proceedings, 2015, Volume: 47, Issue:9 Topics: Acetylcysteine; Animals; Atorvastatin; Catalase; Female; Free Radical Scavengers; Glutathione Peroxidase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Oxidation-Reduction; Oxidative Stress; Peroxidase; Rats; Reperfusion Injury; Superoxide Dismutase	2015
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens. Histology and histopathology, 2008, Volume: 23, Issue:9 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles	2008
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:5 Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kidney Diseases; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation	2011
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:5 Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Evidence-Based Medicine; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Myocardial Infarction; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation	2011
[The effects of atorvastatin on aging kidney]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2011, Volume: 27, Issue:1 Topics: Aging; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Female; Heptanoic Acids; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Wistar; Renal Artery	2011
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart and vessels, 2014, Volume: 29, Issue:1 Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2014
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles	2003
Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. The Journal of urology, 2004, Volume: 172, Issue:6 Pt 1 Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Ureteral Obstruction	2004
Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney & blood pressure research, 2006, Volume: 29, Issue:3 Topics: Albuminuria; Analysis of Variance; Animals; Atorvastatin; Blood Pressure; Caveolin 1; Glomerular Filtration Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Vascular Endothelial Growth Factor A	2006
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease. Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:7 Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure	2006
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British journal of pharmacology, 2006, Volume: 149, Issue:7 Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors	2006
[Effects of atorvastatin on hyperlipidemia in kidney disease patients]. Nihon Jinzo Gakkai shi, 2007, Volume: 49, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis	2007
HMG-CoA reductase inhibitors and renal function. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles	2007
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Lipoprotein profile changes in children after renal transplantation in the modern immunosuppression era. Pediatric transplantation, 2008, Volume: 12, Issue:7 Topics: Adolescent; Adult; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Lipoproteins; Male; Prednisolone; Prevalence; Pyrroles	2008